Eversept Partners LP Takes $6.32 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Eversept Partners LP acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, HoldingsChannel.com reports. The fund acquired 87,140 shares of the biopharmaceutical company’s stock, valued at approximately $6,323,000. Alnylam Pharmaceuticals accounts for 1.8% of Eversept Partners LP’s holdings, making the stock its 16th biggest position.

Several other large investors also recently added to or reduced their stakes in ALNY. State of Alaska Department of Revenue raised its holdings in shares of Alnylam Pharmaceuticals by 1.4% during the second quarter. State of Alaska Department of Revenue now owns 11,061 shares of the biopharmaceutical company’s stock valued at $802,000 after acquiring an additional 152 shares in the last quarter. World Asset Management Inc raised its holdings in shares of Alnylam Pharmaceuticals by 6.0% during the second quarter. World Asset Management Inc now owns 3,190 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 180 shares in the last quarter. Metropolitan Life Insurance Co NY raised its holdings in shares of Alnylam Pharmaceuticals by 3.5% during the first quarter. Metropolitan Life Insurance Co NY now owns 6,557 shares of the biopharmaceutical company’s stock valued at $612,000 after acquiring an additional 221 shares in the last quarter. US Bancorp DE raised its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the second quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 259 shares in the last quarter. Finally, Capital Investment Advisory Services LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $25,000. 94.26% of the stock is owned by hedge funds and other institutional investors.

ALNY traded up $1.71 during trading on Friday, reaching $84.88. The stock had a trading volume of 59,459 shares, compared to its average volume of 668,636. The stock’s 50 day moving average is $79.70 and its two-hundred day moving average is $78.88. The company has a current ratio of 6.28, a quick ratio of 6.16 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $9.30 billion, a price-to-earnings ratio of -11.21 and a beta of 2.35. Alnylam Pharmaceuticals, Inc. has a one year low of $60.27 and a one year high of $99.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The business had revenue of $38.20 million during the quarter, compared to the consensus estimate of $42.24 million. During the same quarter in the prior year, the company earned ($1.61) earnings per share. The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -8.21 earnings per share for the current year.

ALNY has been the subject of a number of recent analyst reports. ValuEngine upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Cowen decreased their target price on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Barclays restated a “buy” rating and set a $125.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 7th. UBS Group upped their target price on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, September 4th. Finally, Goldman Sachs Group reiterated a “neutral” rating and issued a $80.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, May 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $116.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Story: How are institutional investors different from individual investors?

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.